Asklepios Klinik Sankt Augustin GmbH

At Asklepios Klinik Sankt Augustin GmbH, clinical research in pediatric oncology and hematology focuses on major childhood cancers and blood disorders, with studies aimed at improving survival, refining risk-based treatment, and reducing relapse in young patients.

• Studies in acute lymphoblastic leukemia, relapsed ALL, and lymphoblastic lymphoma are testing better ways to improve remission and long-term disease control.
• Research in neuroblastoma, medulloblastoma, and ependymoma is evaluating treatment strategies that may improve outcomes while balancing effectiveness and safety.
• Trials in Ewing sarcoma, malignant germ cell tumours, renal tumours, and myeloid leukemia in children with Down syndrome are exploring more effective cancer care for children and adolescents.

The site’s cancer studies often compare treatment approaches to strengthen event-free survival and guide more personalized therapy for pediatric patients.

The Zentrum fuer Allgemeine Paediatrie und Neonatologie also supports research in pediatric rheumatology, with a strong focus on inflammatory arthritis and related autoimmune conditions in children and adolescents.

• Trials in juvenile idiopathic arthritis, including polyarticular-course JIA and systemic JIA, are assessing new treatments and long-term disease control.
• Studies in juvenile psoriatic arthritis and Still’s disease are evaluating therapies that may reduce inflammation and improve daily function.
• Research is also examining the safety, effectiveness, and body handling of newer immune-targeted medicines for pediatric inflammatory disease.

This work aims to expand treatment options for children with chronic joint and immune-mediated disorders while supporting safer, more tailored care.

Clinical trials at this site include immune system diseases affecting the gut and skin, with research designed to improve symptom control, treatment durability, and overall quality of life in pediatric patients.

• Studies in Crohn’s disease and ulcerative colitis are looking at better ways to manage chronic intestinal inflammation.
• Research in juvenile psoriatic arthritis connects joint and skin-related immune disease, helping clarify how targeted therapies may work across different symptoms.
• Trials of newer biologic and immune-modulating treatments are assessing whether they can offer effective control of inflammation in young people.

These investigations support broader pediatric immunology research by testing therapies that may better match the needs of children with long-lasting inflammatory diseases.

The site participates in studies of nutritional and metabolic diseases, especially type 1 diabetes, with a focus on preserving pancreatic function and improving disease management in children and adolescents.

• Trials in new-onset type 1 diabetes are evaluating whether immune-targeted treatment can help protect insulin-producing cells.
• Research in metabolic care is exploring approaches that may improve long-term disease stability after diagnosis.
• These studies aim to support earlier intervention and better treatment planning for young patients living with chronic metabolic disease.

This area reflects the clinic’s interest in combining pediatric endocrinology with immune-based research to improve outcomes in early diabetes care.

Across several disease areas, the research program at Asklepios Klinik Sankt Augustin GmbH includes trials of newer targeted and immune-based therapies intended to improve treatment effectiveness and understand how these medicines work in children.

• Studies are examining treatment response, safety, and long-term use of newer agents in arthritis, leukemia, and inflammatory bowel disease.
• Some trials focus on whether modern therapies can improve outcomes compared with established approaches in pediatric cancer and autoimmune disease.
• Other research is helping define the role of personalized treatment selection based on disease type and risk profile.

This broad translational effort connects clinical oncology, immunology, and metabolic medicine in a pediatric hospital setting.